


LOCAL ANAESTHETICS

Physiochemical characteristics and clinical relevance Local anaesthetics are **weak bases** and exist predominantly in the **ionised form** at neutral pH as their **pKa exceeds 7.4**. They fall into two groupings **ester or amide**, which describes the linkage between **aromatic lipophilic** group and the **hydrophilic amide group** that each possess. Individual structures confer different physiochemical and clinical characteristics. **Potency** is closely correlated to **lipid solubility** (more so in vitro - but still significantly in vivo). The **duration of action** is closely associated with the extent of **protein binding**. Local anaesthetics with limited protein binding have a short duration of action and conversely those with more extensive protein binding have a longer duration of action. The **onset of action** is closely related to the **pKa**. Local anaesthetics are weak bases and exist mainly in the ionised form at normal pH. Those with a high pKa have a greater fraction present in the ionised form, which is unable to penetrate the phospholipid membrane, resulting in a slow onset of action. Conversely, a low pKa reflects a higher proportion in the un-ionised form and therefore a faster onset of action as more is available to cross the phospholipid membrane. A corollary of this characteristic is the **decreased efficacy** of local anaesthetics in **bacterially infected tissues** which, due to CO₂ production are **acidic** and therefore exacerbates the difference between pKa and pH (in addition there is **increased vasodilation and blood flow** which decreases the anaesthetic efficacy). The **intrinsic vasodilator activity** varies between drugs and influences both the potency and the duration of action. In general local anaesthetics cause vasodilation in low concentrations (lignocaine>bupivacaine>ropivacaine) and vasoconstriction in higher doses.



Local anaesthetic toxicity can be caused by **excessive amounts of the drug** (max doses shown below), by **rapid absorption** and/or by **impaired metabolism** (such as patients with cardiac failure and liver disease). Perhaps more commonly it is seen after **accidental intravascular injection**. Systemic **toxicity** of local anaesthetics is **concentration dependent**, with CNS toxicity occurring at lower concentrations than cardiac toxicity.

Lignocaine blood concentration µg/mL	0	5	10	15	20	25
	Therapeutic range	Mild CNS excitation	Severe CNS excitation	CNS Inhibition	Cardiac depression	
Symptoms	sedation antiarrhythmic effects	tinnitus altered sound perception lightheadedness circumoral numbness paresthesias	agitation confusion muscle twitching tremors seizures	unconsciousness central cardiorespiratory -depression	impaired cardiac conduction decreased contractility cardiac arrest	

More potent local anaesthetics, such as **bupivacaine** and **ropivacaine** also produce systemic **toxicity but at lower levels**. Bupivacaine has extremely high potency at cardiac Na⁺ channels such that the cardiac symptoms occur prior to CNS symptoms. It appears that the **R (+) enantiomer of local anaesthetics has greater affinity for the cardiac Na⁺ channels** which has led to the **development of S (-) enantiomer drugs levobupivacaine and ropivacaine**. Other toxicity issues include anaphylaxis which is generally rare, transient neurological syndrome associated with intrathecal lignocaine and **methemoglobinemia** which is associated with **prilocaine**.

Prevention and management Prevention involves ensuring the patient is **not overdosed** by using the reference values, using with caution in patients with congestive **cardiac failure and liver failure**, and being aware of the **vasculature and risk of direct intravascular injection**. Management of the situation if toxicity is suspected, involves **stopping the injection immediately** and prepare to treat the reaction. **Aggressive resuscitation** is indicated in most cases following ACLS protocols. **Benzodiazepines** are the drugs of choice for seizure control. Phenytoin is not effective and should be avoided. **Propofol** can be used to control seizures but has the risk of potentiating cardiovascular toxicity. In severe reactions, monitor the cardiovascular system (CVS) and support the patient with **intravenous fluids and vasoactives** as required. Small boluses doses of adrenaline are preferred. Vasopressin is not recommended. **Amiodarone is the drug of choice** for ventricular **arrhythmias** due to local anaesthetic toxicity.

	Bupivacaine	Lignocaine
Classification of local anaesthetic (amide / ester)	Amide	Amide
Relative potency (lipid solubility)	8 times more potent	1
Toxic dose	2mg/kg	3mg/kg
Toxic dose with adrenaline	2mg/kg	7mg/kg
Toxic plasma concentration	>1.5 mcg/kg	>5 mcg/kg
Protein binding (duration of action)	95%	70%
Elimination half time	160 minutes	100 minutes
pKa (onset of action)	8.1	7.9
% un-ionised at physiological pH 7.4	15%	25%